市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Citius Oncology, Inc. | 看涨 | - |
AIStockmoo 评分
0.1
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -1.5 |
| 平均 | 0.13 |
|
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 内部持股比例 | 86.80% |
| 机构持股比例 | 0.60% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Arkadios Wealth Advisors | 30 Sep 2025 | 11,666 |
| Yakira Capital Management, Inc. | 30 Jun 2025 | 0 |
| 52周波幅 | ||
| 中 | 6.00 (259.28%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Maxim Group | 23 Sep 2025 | 6.00 (259.28%) | 购买 | 1.81 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合